Variables | β standardised coefficient (95% CI) | Adjusted R2 | p Value |
Total cells (×106/ml) | 0.12 (−943 to 1642) | 0.05 | 0.614 |
Eosinophils (%) | 0.6 (128 to 580) | 0.27 | 0.006 |
Neutrophils (%) | 0.16 (−140 to 284) | −0.02 | 0.506 |
Macrophages (%) | −0.22 (−289 to 101) | −0.001 | 0.355 |
Lymphocytes (%) | 0.07 (−1911 to 2557) | −0.002 | 0.812 |
IL-8 (pg/ml) | −0.23 (−51 to 17) | 0.03 | 0.314 |
ECP (pg/ml) | 0.6 (839 to 3847) | 0.4 | 0.001 |
CystLts (pg/ml) | 0.45 (2 to 64) | 0.39 | 0.004 |
IL-13 (pg/ml) | 0.68 (27 to 85) | 0.45 | 0.001 |
TGF-β1 (pg/ml) | 0.82 (576 to 1144) | 0.68 | <0.001 |
VEGF (pg/ml) | −0.19 (−9 to 4) | 0.03 | 0.450 |
FEV1 (% predicted) | −0.01(−220 to 210) | −0.05 | 0.820 |
FEV1/FVC (% predicted) | 0.08 (−402 to 560) | 0.04 | 0.723 |
FRC (% predicted) | −0.2 (−239 to 50) | 0.04 | 0.215 |
Tlco (% predicted) | 0.09 (−290 to 301) | −0.05 | 0.832 |
Regression analysis was performed after proper adjustments for age, gender, body mass index, atopy and treatment regimens. Non-normally distributed data were logarithmically transformed.
CystLts, cysteinyl leukotrienes; ECP, eosinophilic cationic protein; FEV1, forced expiratory volume in 1 s; FRC, functional residual capacity; FVC, forced vital capacity; IL-8, interleukin 8; IL-13, interleukin-13; OPN, osteopontin; SRA, severe refractory asthma; TGF-β1, transforming growth factor β; Tlco, carbon monoxide transfer factor; VEGF, vascular endothelial growth factor.